Ankylosing Spondylitis Clinical Trials

A listing of Ankylosing Spondylitis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Alabama

UPDATED

Anniston Alabama

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

Arizona

UPDATED

Glendale Arizona 85306

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Peoria Arizona 85381

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Phoenix Arizona 85037

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Phoenix Arizona 85032

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

California

UPDATED

Fremont California 94538

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

San Diego California

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

San Francisco California

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Upland California

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

Florida

UPDATED

Aventura Florida

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Fort Lauderdale Florida

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Ormond Beach Florida

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Sarasota Florida

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

St. Petersburg Florida 33705

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

View More ▼

UPDATED

Tampa Florida 33614

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Venice Florida

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

Idaho

UPDATED

Meridian Idaho 83642

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Illinois

UPDATED

Chicago Illinois 60612

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Louisiana

UPDATED

Monroe Louisiana 71203

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Massachusetts

UPDATED

Boston Massachusetts

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

Minnesota

UPDATED

Eagan Minnesota

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

New Jersey

UPDATED

Freehold New Jersey

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

New York

UPDATED

Orchard Park New York 14127

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Ohio

UPDATED

Cleveland Ohio

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

Oregon

UPDATED

Portland Oregon

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Portland Oregon 97239-3098

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Pennsylvania

UPDATED

Duncansville Pennsylvania

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Duncansville Pennsylvania 16635

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Wyomissing Pennsylvania 19610

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

South Carolina

UPDATED

Charleston South Carolina

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

Tennessee

UPDATED

Jackson Tennessee 38305

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Texas

UPDATED

Austin Texas

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Austin Texas 78731

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Dallas Texas

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Dallas Texas

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Mesquite Texas 75150

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Virginia

UPDATED

Arlington Virginia 22205

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Washington

UPDATED

Seattle Washington

A clinical research study of Placebo and Bimekizumab for the treatment of Ankylosing Spondylitis

UPDATED

Seattle Washington 98133

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Argentina

UPDATED

Buenos Aires C1204AAP

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Ciudad de Buenos Aires C1430EGF

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Ciudad de Buenos Aires C1428DQG

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Ciudad De La Plata B1902

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Ciudad De San Miguel De Tucuman T4000AXL

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

View More ▼

UPDATED

Cordoba 5000

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

Belgium

UPDATED

Brussels 1200

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Brussels 1070

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Genk 3600

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Ghent 9000

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)

UPDATED

Leuven 3000

Patients are needed to participate in a clinical research study of Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg and Golimumab 50 mg to evaluate Axial Spondyloarthritis, Anti-TNF(Alpha)